Inside the Aids virus: Research finds chink in the armour that protects HIV in breakthrough that could lead to a new class of drugs
Discovery could help form new pills to strike at the infection just as it starts to attack
Steve Connor is the Science Editor of The Independent. He has won many awards for his journalism, including five-times winner of the prestigious British science writers’ award; the David Perlman Award of the American Geophysical Union; twice commended as specialist journalist of the year in the UK Press Awards; UK health journalist of the year and a special merit award of the European School of Oncology for his investigative journalism. He has a degree in zoology from the University of Oxford and has a special interest in genetics and medical science, human evolution and origins, climate change and the environment.
Wednesday 29 May 2013
Scientists have for the first time built a detailed molecular model of the shell-like “inner sanctum” within the Aids virus, opening the door to potential new treatments.
The cone-shaped “capsid” is what protects the virus’s lethal package of genetic material until the time comes to release it inside a human cell.
The breakthrough could enable researchers to find new ways of attacking the integrity of the capsid, in order to interfere with the virus’s ability to replicate itself once it enters the body.
Researchers said their findings could lead to a new class of drug that could complement the existing anti-retroviral Aids medications, some of which have led to resistant forms of HIV as well as causing serious side-effects in some patients.
Using a combination of high-magnification microscopy, detailed X-ray analysis, and ultra-fast supercomputers, the researchers were able to piece together the precise positions of millions of atoms within the 1,300 proteins that form the capsid’s unusual structure.
Although the capsid’s overall shape has been known about for many years, this is the first study to reveal the precise position of the structural proteins that form its three-dimensional cone, which could lead to a new generation of anti-HIV drugs based on destroying the capsid’s vital function.
“The HIV capsid has actually two completely opposite properties. It has to protect the genetic material but, once it gets inside the cell, it has to release the genetic material,” said Professor Klaus Schulten of the University of Illinois based at Urbana-Champaign.
“That has to happen with really good timing. Too quick is not good, too slow is not good. And this is a moment when you can throw a wrench into the system,” said Professor Schulten, one of the authors of the study published in the journal Nature.
“The timing of the opening of the capsid is essential for the degree of virulence of the virus. This is where we could perhaps best interfere with HIV infection,” he said.
The work revealed that the capsid’s shell, inset below, is composed of a matrix of identical proteins linked in a complicated lattice of 200 hexagons. These are composed of six protein sub-units, which form the flat surfaces of the capsid, and about 12 pentagons of five sub-units each, which form the curved corners at the two ends of the capsid.
“The capsid is critically important for HIV replication, so knowing its structure in detail could lead us to new drugs that can treat or prevent the infection,” said Peijun Zhang of the University of Pittsburgh, a co-author of the study. “This approach has the potential to be a powerful alternative to our current HIV therapies, which work by targeting certain enzymes, but drug resistance is an enormous challenge due to the virus’s high mutation rate,” Dr Zhang said.
Immensely powerful supercomputers revealed the precise geometric positions of the capsid’s protein building blocks, showing critical molecular interactions at the “seams” or interfaces of the capsid, which could be vulnerable to attack.
“The capsid is very sensitive to mutation, so if we can disrupt those interfaces, we could interfere with capsid function. The capsid has to remain intact to protect the HIV genome and get it into the human cell,” Dr Zhang added.
“But, once inside, it has to come apart to release its contents so that the virus can replicate. Developing drugs that cause capsid dysfunction by preventing its assembly or disassembly might stop the virus from reproducing,” she said.
- 1 Howard Jacobson: Let's see the 'criticism' of Israel for what it really is
- 2 Instagram of US airport security chiefs: Lipstick knives and IED training kits among items seized
- 3 Brazil vs Germany World Cup 2014: In defence of Mesut Ozil - the Arsenal midfielder works magic in the shadows
- 4 PornHub begs users to stop uploading video clips of Brazil getting beaten 7-1
- 5 Tony Abbott embarrasses Australia by praising Japanese WWII military, ‘getting on the sake’ and posing for ‘crotch-shot’ photo opportunity
Game of Thrones author George RR Martin says 'f*** you' to fans who fear he will die before finishing Westeros saga
Jennifer Lawrence face palms Emma Watson at Christian Dior show in Paris
Instagram of US airport security chiefs: Lipstick knives and IED training kits among items seized
Mick Jagger denies being World Cup curse and reason for Brazil’s embarrassing defeat
Gingers face extinction due to climate change, scientists warn
Sustained immigration has not harmed Britons' employment, say government advisers
British jihadist calls for 'flag of Islam' over Downing Street and Buckingham Palace
Australia facing international condemnation after turning around Sri Lankans at sea
7/7 memorial defaced on anniversary of 2005 attacks with ‘Blair lied thousands died’ graffiti
Even when it brutalises one of its own teenage citizens, America is helpless against Israel
There’s a nasty smell in the political air – and it’s coming from the Tories
£60000 - £75000 per annum: Harrington Starr: Business Analyst Consultant (Fina...
£60000 per annum: Harrington Starr: A leading provider in investment managemen...
£600 - £700 per day: Harrington Starr: AVS, JVS Openlink Endur Developer JVS, ...
£45000 - £60000 per annum + competitive: Progressive Recruitment: Exciting opp...